

Mostafa M Hamed

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5924624/publications.pdf>

Version: 2024-02-01

20
papers

486
citations

840776

11
h-index

713466

21
g-index

23
all docs

23
docs citations

23
times ranked

777
citing authors

#	ARTICLE	IF	CITATIONS
1	Design, synthesis and anticancer evaluation of novel tetrahydroquinoline derivatives containing sulfonamide moiety. <i>European Journal of Medicinal Chemistry</i> , 2009, 44, 4211-4217.	5.5	108
2	Synthesis and in vitro anticancer evaluation of some novel hexahydroquinoline derivatives having a benzenesulfonamide moiety. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 201-207.	5.5	69
3	Antifungal potential of marine natural products. <i>European Journal of Medicinal Chemistry</i> , 2017, 126, 631-651.	5.5	69
4	Synthesis and biological evaluation of 2-amino-7,7-dimethyl 4-substituted-5-oxo-1-(3,4,5-trimethoxy)-1,4,5,6,7,8-hexahydro-quinoline-3-carbonitrile derivatives as potential cytotoxic agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 6939-6942.	2.2	55
5	A New PqsR Inverse Agonist Potentiates Tobramycin Efficacy to Eradicate <i>Pseudomonas aeruginosa</i> Biofilms. <i>Advanced Science</i> , 2021, 8, e2004369.	11.2	34
6	First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF- κ B Activity As Novel Anticancer Agents. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 2853-2868.	6.4	28
7	Synthesis and Biological Evaluation of Cystobactamid 507: A Bacterial Topoisomerase Inhibitor from <i>Cystobacter</i> sp.. <i>Synlett</i> , 2015, 26, 1175-1178.	1.8	20
8	Synthetic studies of cystobactamids as antibiotics and bacterial imaging carriers lead to compounds with high <i>in vivo</i> efficacy. <i>Chemical Science</i> , 2020, 11, 1316-1334.	7.4	20
9	Cystobactamid 507: Concise Synthesis, Mode of Action, and Optimization toward More Potent Antibiotics. <i>Chemistry - A European Journal</i> , 2020, 26, 7219-7225.	3.3	18
10	6-Aryl and Heterocycle Quinazoline Derivatives as Potent EGFR Inhibitors with Improved Activity toward Gefitinib Sensitive and Resistant Tumor Cell Lines. <i>ChemMedChem</i> , 2013, 8, 1495-1504.	3.2	16
11	Quinazoline and tetrahydropyrido-thieno[2,3-d]pyrimidine derivatives as irreversible EGFR tyrosine kinase inhibitors: influence of the position 4 substituent. <i>MedChemComm</i> , 2013, 4, 1202.	3.4	16
12	Design and synthesis of novel flexible ester-containing analogs of tamoxifen and their evaluation as anticancer agents. <i>Future Medicinal Chemistry</i> , 2016, 8, 249-256.	2.3	10
13	Development of potential preclinical candidates with promising <i>in vitro</i> ADME profile for the inhibition of type 1 and type 2 17 β -Hydroxysteroid dehydrogenases: Design, synthesis, and biological evaluation. <i>European Journal of Medicinal Chemistry</i> , 2019, 178, 93-107.	5.5	6
14	Divergent synthesis and biological evaluation of 2-(trifluoromethyl)pyridines as virulence-attenuating inverse agonists targeting PqsR. <i>European Journal of Medicinal Chemistry</i> , 2021, 226, 113797.	5.5	5
15	Structure-Guided Optimization of Small-Molecule Folate Uptake Inhibitors Targeting the Energy-Coupling Factor Transporters. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 8869-8880.	6.4	3
16	Design and Synthesis of Novel Bis-Imidazolyl Phenyl Butadiyne Derivatives as HCV NS5A Inhibitors. <i>Pharmaceuticals</i> , 2022, 15, 632.	3.8	2
17	Development of (4-Phenylamino)quinazoline Alkylthiourea Derivatives as Novel NF- κ B Inhibitors. <i>Pharmaceuticals</i> , 2022, 15, 778.	3.8	2
18	From EGFR kinase inhibitors to anti-inflammatory drugs: Optimization and biological evaluation of (4-(phenylamino)quinazolyl)-phenylthiourea derivatives as novel NF- κ B inhibitors. <i>Bioorganic Chemistry</i> , 2022, 127, 105977.	4.1	2

#	ARTICLE	IF	CITATIONS
19	Design and Synthesis of Novel Quinazoline Derivatives and Their Evaluation as PI3Ks Inhibitors. Chemical and Pharmaceutical Bulletin, 2014, 62, 1166-1172.	1.3	1
20	Redesigning of the cap conformation and symmetry of the diphenylethyne core to yield highly potent pan-genotypic NS5A inhibitors with high potency and high resistance barrier. European Journal of Medicinal Chemistry, 2022, 229, 114034.	5.5	1